News

Here's Why Viking Therapeutics Bounced Back Today

Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

Viking Therapeutics (VKTX) Slashes 42% on Huge Clinical Study Dropout Rate

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...
Zacks.com on MSN14h

Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Viking Therapeutics Slumps as Weight-Loss Pill Study Underwhelms

Viking Therapeutics Inc. plunged in early trading on Tuesday after its experimental obesity pill disappointed in a mid-stage ...

Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data

The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.
BioSpace1d

Viking Crashes as Obesity Pill Delivers Over 12% Weight Loss

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...

Viking Therapeutics plunges after mid-stage trial data for oral weight loss drug

Viking Therapeutics (VKTX) stock drops even as a mid-stage trial for its oral weight loss drug VK2735 succeeds. Novo (NVO) ...